Frontiers in Oncology (Dec 2022)

Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients

  • Javier David Benitez Fuentes,
  • Kauzar Mohamed Mohamed,
  • Alicia de Luna Aguilar,
  • Carlos Jiménez García,
  • Kissy Guevara-Hoyer,
  • Kissy Guevara-Hoyer,
  • Miguel Fernandez-Arquero,
  • Miguel Fernandez-Arquero,
  • M Antonia Rodríguez de la Peña,
  • Laura Garciía Bravo,
  • Alejandro Francisco Jiménez Ortega,
  • Paloma Flores Navarro,
  • Jorge Bartolome Arcilla,
  • Bárbara Alonso Arenilla,
  • Elvira Baos Muñoz,
  • Alberto Delgado-Iribarren García-Campero,
  • María Montealegre Sanz,
  • Silvia Sanchez-Ramon,
  • Silvia Sanchez-Ramon,
  • Pedro Perez Segura

DOI
https://doi.org/10.3389/fonc.2022.975980
Journal volume & issue
Vol. 12

Abstract

Read online

IntroductionEvidence is scant regarding the long-term humoral and cellular responses Q7 triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in cancer patients after repeated booster doses. The possibility of T-cell exhaustion following these booster doses in this population has not yet been fully studied and remains uncertain.MethodsIn this single-center prospective observational study, we explored the specific humoral and cellular response to S1 antigen in 36 patients with solid malignancies at baseline, and after the second and third doses of the mRNA-1273 vaccine.ResultsA dual behavior was observed: 24 (66.7%) patients showed partial specific IFN-γ response after the second dose that was further enhanced after the third dose; and 11 (30.5%) already showed an optimal response after the second dose and experienced a marked fall-off of specific IFN-γ production after the third (4 patients negativization), which might suggest T cell exhaustion due to repetitive priming to the same antigen. One (2.8%) patient had persistently negative responses after all three doses. Seroconversion occurred in all patients after the second dose. We then studied circulating exhausted CD8+ T-cells in 4 patients from each of the two response patterns, those with increase and those with decrease in cellular response after the third booster. The patients with decreased cellular response after the booster had a higher expression of PD1+CD8+ and CD57+PD1+CD8+ exhausted T cells compared with those with an increased cellular response both in vivo and in vitro. The proportion of PD1+CD8+ and CD57+PD1+CD8+ exhausted T cells inversely correlated with IFN-γ production.DiscussionOur preliminary data show that the two-dose SARS-CoV-2 vaccine regimen was beneficial in all cancer patients of our study. An additional booster seems to be beneficial in suboptimal vaccine seroconverters, in contrast to maximal responders that might develop exhaustion. Our data should be interpreted with caution given the small sample size and highlight the urgent need to validate our results in other independent and larger cohorts. Altogether, our data support the relevance of immunological functional studies to personalize preventive and treatment decisions in cancer patients.

Keywords